BEVERLY, MA–(Marketwire – Jun 20, 2011) – Cellceutix Corporation (OTCQB: CTIX) (PINKSHEETS: CTIX) today reported that its anti-cancer compound, Kevetrin™, has demonstrated potent anti-tumor activity in the treatment of a pancreatic carcinoma cell line in a xenograft tumor model. After three weeks of studies, results testing Kevetrin™ against Pancreatic Carcinoma Cell line MIA-PaCa-2 showed average tumor volume shrinkage of 67% and a tumor growth delay of greater than 94% with no significant weight loss in the animals.
Given the strong results, Cellceutix is continuing to treat animals with Kevetrin™ for a second cycle to further evaluate efficacy. Additional cycles of administration could also establish that Kevetrin does not induce resistance to the cancer cells.
“Kevetrin™ simply continues to impress,” stated Dr. Krishna Menon, CSO of Cellceutix. “In reality, the nearly 100% tumor growth delay was underestimated as the tumors in one of the Kevetrin treated mice never reached 500mm3. Therefore, it had to be omitted from that set of data; otherwise the figure would have been even higher. Preliminary data from the second cycle of dosing, initiated when tumors had reached 2200mm3, is again showing reduction of tumor growth, reinforcing the idea of no resistance towards Kevetrin™ developing and the sheer potency of our compound. In all my years as a researcher, I have never seen anything like Kevetrin™.”
“We look forward to providing our investors with a multitude of data and updates in the upcoming weeks,” commented Cellceutix CEO Leo Ehrlich. “We are eagerly awaiting the conclusion of the pancreatic research. Additionally, we are reaching the final stages of the procedural process with one of the United States’ most prominent cancer centers regarding the Phase I clinical trial which we will be able to disclose shortly. The culmination of this process is the filing of the Investigational New Drug Application (IND) with the US FDA.”